An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes

Proteome Science

Volumn 10, Issue 1, 2012, Pages

  Mahlknecht, Philipp ^a   Stemberger, Sylvia ^a   Sprenger, Fabienne ^a   Rainer, Johannes ^a   Hametner, Eva ^a   Kirchmair, Rudolf ^a   Grabmer, Christoph ^b   Scherfler, Christoph ^a   Wenning, Gregor K ^a   Seppi, Klaus ^a   Poewe, Werner ^a   Reindl, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIBODY MICROARRAY ANALYSIS; ARTICLE; COHORT ANALYSIS; CORTICOBASAL SYNDROME; DEMENTIA; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; SHY DRAGER SYNDROME;

PARKINSONIA;

EID: 84869881236     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-10-71     Document Type: Article

References (33)

1. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009, 5:561-570. 10.1038/nrneurol.2009.135, 19724250.
2. Graeber MB. Biomarkers for Parkinson's disease. Exp Neurol 2009, 216:249-253. 10.1016/j.expneurol.2008.12.017, 19166835.
3. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726. 10.1093/brain/awq008, 2842513, 20157014.
4. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240. 10.1016/S1474-4422(11)70014-X, 21317042.
5. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772. 10.1212/WNL.0b013e3181fd613b, 20962290.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269. 10.1016/j.jalz.2011.03.005, 3312024, 21514250.
7. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362. 10.1038/nm1653, 17934472.
8. O''Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010, 67:1077-1081. 10.1001/archneurol.2010.215, 3069805, 20837851.
9. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011, 32:539-540. 10.1016/j.neurobiolaging.2009.03.011, 19395124.
10. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012, 7:e29868. 10.1371/journal.pone.0029868, 3261152, 22279551.
11. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann GR, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011, 69:655-663. 10.1002/ana.22271, 3155276, 21520231.
12. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007, 150:963-976. 2013918, 17339843.
13. Scalzo P, Kummer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009, 216:122-125. 10.1016/j.jneuroim.2009.08.001, 19732964.
14. Scalzo P, Kummer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol 2010, 257:540-545. 10.1007/s00415-009-5357-2, 19847468.
15. Scalzo P, Kummer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010, 468:56-58. 10.1016/j.neulet.2009.10.062, 19857551.
16. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001, 22:724-763. 10.1210/er.22.6.724, 11739329.
17. Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso RD. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response. J Neural Transm 1981, 51:123-134. 10.1007/BF01664010, 7264625.
18. Martignoni E, Horowski R, Liuzzi A, Costa A, Dallabonzana D, Cozzi R, et al. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol 1996, 19:72-80. 10.1097/00002826-199619010-00006, 8867520.
19. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312. 10.1101/gad.1653708, 2732412, 18483217.
20. Nikkhah G, Odin P, Smits A, Tingstrom A, Othberg A, Brundin P, et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res 1993, 92:516-523.
21. Nakao N, Brundin P, Funa K, Lindvall O, Odin P. Platelet-derived growth factor exerts trophic effects on rat striatal DARPP-32-containing neurons in culture. Exp Brain Res 1994, 101:291-296.
22. Pietz K, Odin P, Funa K, Lindvall O. Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. Neurosci Lett 1996, 204:101-104. 10.1016/0304-3940(96)12326-0, 8929988.
23. Mohapel P, Frielingsdorf H, Haggblad J, Zachrisson O, Brundin P. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 2005, 132:767-776. 10.1016/j.neuroscience.2004.11.056, 15837137.
24. Olson L, Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010, 45:41-46. 10.1016/j.exger.2009.10.011, 19853649.
25. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
26. Fiedler J, Roderer G, Gunther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 2002, 87:305-312. 10.1002/jcb.10309, 12397612.
27. Abboud SL. A bone marrow stromal cell line is a source and target for platelet-derived growth factor. Blood 1993, 81:2547-2553.
28. Ozaki Y, Nishimura M, Sekiya K, Suehiro F, Kanawa M, Nikawa H, et al. Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev 2007, 16:119-129. 10.1089/scd.2006.0032, 17348810.
29. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 2010, 66:144-156. 10.1227/01.NEU.0000363149.58885.2E, 2811094, 20023545.
30. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009, 8:270-279. 10.1016/S1474-4422(09)70042-0, 19233037.
31. Ling H, O'Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010, 133:2045-2057. 10.1093/brain/awq123, 20584946.
32. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
33. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:3.